Trial Profile
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone (Primary) ; Palonosetron (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 23 Dec 2015 New trial record